Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Ligand-mediated dephosphorylation signaling for MAP kinase.

Shults NV, Almansour FS, Rybka V, Suzuki DI, Suzuki YJ.

Cell Signal. 2018 Dec;52:147-154. doi: 10.1016/j.cellsig.2018.09.005. Epub 2018 Sep 10.

PMID:
30213686
2.

Neurotensin stimulates protein kinase C-dependent mitogenic signaling in human pancreatic carcinoma cell line PANC-1.

Guha S, Lunn JA, Santiskulvong C, Rozengurt E.

Cancer Res. 2003 May 15;63(10):2379-87.

3.

Regulation of mitogen-activated protein kinase phosphatase-1 in vascular smooth muscle cells.

Bokemeyer D, Lindemann M, Kramer HJ.

Hypertension. 1998 Oct;32(4):661-7.

PMID:
9774360
4.
5.

mTORC1 inhibition increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON.

Li J, Liu J, Song J, Wang X, Weiss HL, Townsend CM Jr, Gao T, Evers BM.

Am J Physiol Cell Physiol. 2011 Jul;301(1):C213-26. doi: 10.1152/ajpcell.00067.2011. Epub 2011 Apr 20.

6.

PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.

Aksamitiene E, Kholodenko BN, Kolch W, Hoek JB, Kiyatkin A.

Cell Signal. 2010 Sep;22(9):1369-78. doi: 10.1016/j.cellsig.2010.05.006. Epub 2010 May 12.

7.

Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.

Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.

Cancer Res. 2004 Oct 1;64(19):7156-68.

8.

Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.

Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM.

J Pharmacol Exp Ther. 2009 Jun;329(3):1063-70. doi: 10.1124/jpet.108.147306. Epub 2009 Mar 3.

PMID:
19258520
9.

Role of mitogen-activated protein kinase/extracellular signal-regulated kinase cascade in gonadotropin-releasing hormone-induced growth inhibition of a human ovarian cancer cell line.

Kimura A, Ohmichi M, Kurachi H, Ikegami H, Hayakawa J, Tasaka K, Kanda Y, Nishio Y, Jikihara H, Matsuura N, Murata Y.

Cancer Res. 1999 Oct 15;59(20):5133-42.

10.
11.

Signaling molecules involved in coupling growth hormone receptor to mitogen-activated protein kinase activation.

Vanderkuur JA, Butch ER, Waters SB, Pessin JE, Guan KL, Carter-Su C.

Endocrinology. 1997 Oct;138(10):4301-7.

PMID:
9322943
12.
13.

MEK1/2 inhibitors in the treatment of gynecologic malignancies.

Miller CR, Oliver KE, Farley JH.

Gynecol Oncol. 2014 Apr;133(1):128-37. doi: 10.1016/j.ygyno.2014.01.008. Epub 2014 Jan 14. Review.

PMID:
24434059
14.
15.

Dissociation of angiotensin II-stimulated activation of mitogen-activated protein kinase kinase from vascular contraction.

Watts SW, Florian JA, Monroe KM.

J Pharmacol Exp Ther. 1998 Sep;286(3):1431-8.

PMID:
9732408
17.
18.

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C.

Cancer Res. 2006 Dec 15;66(24):11851-8.

19.

Follicle-Stimulating Hormone (FSH)-dependent Regulation of Extracellular Regulated Kinase (ERK) Phosphorylation by the Mitogen-activated Protein (MAP) Kinase Phosphatase MKP3.

Donaubauer EM, Law NC, Hunzicker-Dunn ME.

J Biol Chem. 2016 Sep 9;291(37):19701-12. doi: 10.1074/jbc.M116.733972. Epub 2016 Jul 15.

20.

Supplemental Content

Support Center